oxalic acid tert-butyl N-{9-azabicyclo[5.3.1]undecan-11-yl}carbamate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: oxalic acid tert-butyl N-{9-azabicyclo[5.3.1]undecan-11-yl}carbamate
• 英文别名: tert-butyl N-(9-azabicyclo[5.3.1]undecan-11-yl)carbamate;oxalic acid
• 化学式: C17H30N2O6
• mdl: MFCD28125242
• 分子量: 358.4
• InChiKey: BDWQJUJVYYRHTC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.34
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.823
• 拓扑面积：
  125
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• Carboxamide-pyrimidine derivatives as SHP2 antagonists
  申请人：Merck Patent GmbH

  公开号：US11033547B2

  公开（公告）日：2021-06-15

  The invention relates to carboxamide-pyrimidine derivatives of the general formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.

  本发明涉及通式 I 的羧酰胺-嘧啶衍生物、 或其药学上可接受的盐，以及本发明化合物用于治疗哺乳动物（尤其是人类）增殖过度疾病和失调的用途，以及含有此类化合物的药物组合物。
• CARBOXAMIDE-PYRIMIDINE DERIVATIVES AS SHP2 ANTAGONISTS
  申请人：Merck Patent GmbH

  公开号：US20200281926A1

  公开（公告）日：2020-09-10

  The invention relates to carboxamide-pyrimidine derivatives of the general formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.